NCT06033781

Brief Summary

The goal of this clinical trial is to assess the efficacy of CBT-NC intervention to determine its impact on mental health and suicidality in children ages 6-17. The main aims are: Aim 1: Examine CBT-NC efficacy for improving nightmare distress and frequency in youth with chronic nightmares by comparing the treatment and waitlist group. Aim 2: Examine whether improvements in nightmares relate to fewer mental health problems for youth by determining by comparing the treatment and waitlist group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
57

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2023

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 7, 2023

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

September 5, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 13, 2023

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2026

Completed
Last Updated

April 23, 2026

Status Verified

April 1, 2026

Enrollment Period

2.7 years

First QC Date

September 5, 2023

Last Update Submit

April 20, 2026

Conditions

Keywords

CBTCognitiveBehavioralTherapy

Outcome Measures

Primary Outcomes (5)

  • Changes in reports on Sleep Journal

    The sleep journal is a 3 question self report regarding nightmares.

    Participants complete this daily from consent to baseline assessment (Week 0), during treatment, and before post-assessments, up to 20 weeks. They also complete a weekly version for 4 weeks following post-assessments (Weeks 10-14).

  • Change in Nightmare Disorder Diagnoses from Structure Clinical Interview for Sleep Disorders in Children (SCISD-Kid)

    The SCISD-Kid is a structured clinical interview that assesses for sleep disorders. The main module interest is the nightmare disorder module.

    Participants will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

  • Change on the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a yes/no questionnaire to assess for suicidal ideations and behaviors. For this study, we will be looking at the 5 suicidal ideation questions.

    Participants will be assessed at baseline (Week 0), at post-assessments, up to 20 weeks, and weekly following their post-assessment for 4 weeks.

  • Change on the Strengths and Difficulties Questionnaire (SDQ) - Caregiver Version

    The SDQ is a 25-item brief behavioral screening questionnaire for detecting mental health problems in general populations people aged 2-17. It assesses three scales for internalizing problems (10 items), externalizing problems (10 items), and prosocial behavior (5 items). The internalizing and externalizing scales have scores ranging from 0 to 20 with higher scores indicating more difficulties. The prosocial behavior scale ranges from 0 to 10 with higher scores indicating more prosocial behaviors.

    Participants' caregivers will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

  • Change on the Patient Health-Questionnaire-9 (PHQ-9)

    The PHQ-9 is a 9-question Likert scale questionnaire to assess for depression. The items are scored on a scale of 0-27. Total scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe, and severe depression, respectively.

    Participants will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

Secondary Outcomes (6)

  • Change on the Child Adolescent Trauma Screen (CATS) - Child Version

    Participants will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

  • Change on the Patient Health-Questionnaire-2 (PHQ-2)

    Participants will be assessed at baseline (Week 0), at post-assessments, up to 20 weeks, and weekly following their post-assessment for 4 weeks.

  • Change on the Child Adolescent Trauma Screen (CATS) - Caregiver Version

    Participants' caregivers will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

  • Change on Sleep Locus of Control (SLOC)

    Participants and caregivers will be assessed at baseline (Week 0), post-assessments, and weekly during therapy, up to 20 weeks.

  • Change on Nightmare Locus of Control (NLOC)

    Participants and caregivers will be assessed at baseline (Week 0), post-assessments, and weekly during therapy, up to 20 weeks.

  • +1 more secondary outcomes

Study Arms (2)

Treatment Right-Away

EXPERIMENTAL

Child will start the CBT-NC treatment right away.

Behavioral: Cognitive Behavioral Therapy for Nightmares in Children

Waitlist Control

NO INTERVENTION

Waitlist control group will complete the assessments at the same time as the treatment group, without receiving any treatment. They will be offered treatment after finishing the waitlist.

Interventions

The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.

Treatment Right-Away

Eligibility Criteria

Age6 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Child must be between ages of 6-17 years 11 months.
  • Child must report recurrent nightmares that meet Diagnostic and Statistical Manual of Mental Disorders criteria for nightmare disorder.
  • Child must speak and understand English at no less than a 6-year-old level.
  • Children on prescribed psychotropic medications must be stable for 30 days prior to enrolling.
  • Child must have a parent or legal guardian attend study visits with them.
  • Participants must have access to WIFI/phone data in order to participate in this study and must have an electronic device with a camera enabled.

You may not qualify if:

  • Children with a diagnosis of sleep apnea which is not adequately treated.
  • Children whose receptive/expressive language skills are below a 6-year-old level.
  • If it is determined that a child is actively suicidal and at imminent risk for self-harm, the family will be notified and referred for immediate care. They will not be eligible for the study until they are deemed stable.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Tulsa

Tulsa, Oklahoma, 74104, United States

Location

University of Oklahoma School of Community Medicine

Tulsa, Oklahoma, 74135, United States

Location

MeSH Terms

Conditions

Suicidal IdeationBehavior

Interventions

Cognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

SuicideSelf-Injurious BehaviorBehavioral Symptoms

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Lisa Cromer, PhD

    University of Tulsa

    PRINCIPAL INVESTIGATOR
  • Tara Buck, MD

    University of Oklahoma

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 5, 2023

First Posted

September 13, 2023

Study Start

August 7, 2023

Primary Completion

April 15, 2026

Study Completion

April 15, 2026

Last Updated

April 23, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations